NET-Associated Transcriptional Signatures and T-Cell Functional States During Allogeneic CAR-γδT-Cell Therapy: A Longitudinal Single-Cell Analysis
Related Experiment Video
Updated: Oct 28, 2026

Isolation, Cultivation, and Transient Transfection of Primary Human T Cells to Generate Chimeric Antigen Receptor (CAR) T Cells
Published on: March 27, 2026
Lingsong Yao1, Zhiyu Liu2, Ying Wang1
1State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China.
Background:
CAR T-cell therapy has transformed the treatment of hematologic malignancies, although conventional autologous αβ CAR-T products remain limited by complex manufacturing, variable persistence, and relapse risk. γδT cells provide a promising donor source for next-generation off-the-shelf CAR-T therapies due to their MHC-independent tumor recognition, potent cytotoxicity, and minimal risk of graft-versus-host disease; however, the determinants of treatment durability following allogeneic CAR-γδT-cell therapy remain poorly defined. NETs have recently emerged as key immunoregulatory components of the TME, where excessive NET formation sustains inflammation, reshapes immune-stromal interactions, and impairs lymphocyte function, yet their impact on CAR-T-cell fate is largely unknown.
Methods:
In this study, we performed longitudinal single-cell transcriptomic profiling of patients treated with allogeneic CAR-γδT cells and integrated ligand-receptor inference, pathway enrichment, and transcriptional regulatory analyses.
Results:
We identified a 69-gene NET-associated transcriptional signature in the neutrophil population captured in PBMC samples. The NET-associated transcriptional score increased longitudinally in the single patient who subsequently relapsed, whereas longitudinal patterns varied across individual patients. Exploratory analyses identified associations between NET-associated transcriptional activity and T-cell functional programs, including an inverse association with proliferation. NicheNet, pathway enrichment, and SCENIC analyses highlighted candidate inflammatory and regulatory programs involving IL-1-related signaling, adhesion pathways, SMAD3 regulon activity, and E2F-related proliferative programs. Analysis of an independent cohort provided supportive evidence for related inflammatory transcriptional patterns, although differences in therapeutic platform and cellular composition limited direct validation.
Discussion:
Together, these findings suggest that NET-associated inflammatory states may be linked to peripheral immune remodeling and altered circulating T-cell functional states during CAR-γδT-cell therapy. Larger longitudinal cohorts, more comprehensive clinical annotation, and orthogonal measurements of NET formation are needed to establish the clinical and mechanistic significance of these associations.

